BMS-986165, an Oral, Selective TYK2 Inhibitor, in the Treatment of Moderate to Severe Psoriasis as Assessed by the Static Physician's Global Assessment (sPGA)/Body Surface Area (BSA) Composite Tool (sPGAxBSA), a Clinically Useful Alternative to PASI
Main Article Content
Keywords
Psoriasis, Tyrosine Kinase Inhibitor
Abstract
Abstract not available.
References
1. Spuls PI et al. J Invest Dermatol. 2010;130:933-943.
2. Walsh JA et al. J Am Acad Dermatol. 2013;69:931-937.
3. Duffin KC et al. J Drugs Dermatol. 2017;16:147-153.
4. Gottlieb AB et al. Dermatology. 2019;235:348-354.
5. Merola JF et al. J Invest Dermatol. 2018;138:1955-1961.
6. Watford WT et al. Immunol Rev. 2004;202:139-156.
7. Tokarski JS et al. J Biol Chem. 2015;290:11061-11074.
8. Volpe E et al. Nat Immunol. 2008;9:650-657.
9. Geremia A et al. J Exp Med. 2011;208:1127-1133.
10. Tucci M et al. Clin Exp Immunol. 2008;154:247-254.
11. Gillooly K et al. Arthritis Rheumatol. 2016;68(suppl10):abstract 11L.
12. Papp K et al. N Engl J Med. 2018;379:1313-1321.
13. Gottlieb AB et al. J Am Acad Dermatol. 2017;77:1178-1180.
2. Walsh JA et al. J Am Acad Dermatol. 2013;69:931-937.
3. Duffin KC et al. J Drugs Dermatol. 2017;16:147-153.
4. Gottlieb AB et al. Dermatology. 2019;235:348-354.
5. Merola JF et al. J Invest Dermatol. 2018;138:1955-1961.
6. Watford WT et al. Immunol Rev. 2004;202:139-156.
7. Tokarski JS et al. J Biol Chem. 2015;290:11061-11074.
8. Volpe E et al. Nat Immunol. 2008;9:650-657.
9. Geremia A et al. J Exp Med. 2011;208:1127-1133.
10. Tucci M et al. Clin Exp Immunol. 2008;154:247-254.
11. Gillooly K et al. Arthritis Rheumatol. 2016;68(suppl10):abstract 11L.
12. Papp K et al. N Engl J Med. 2018;379:1313-1321.
13. Gottlieb AB et al. J Am Acad Dermatol. 2017;77:1178-1180.